Cipla Limited announced its submission of an Abbreviated New Drug Application (ANDA) for fluticasone propionate and salmeterol inhalation powder (100/50 mcg, 250/50 mcg and 500/50 mcg) to the United States Food and Drug Administration (FDA).
The company had recently announced the successful completion of its phase-3 clinical end-point study for the product in the first attempt.
The product is the generic version of GSK's Advair Diskus. It is indicated as a twice-daily prescription medicine to treat asthma in patients aged four years and older. It is also used in the long term to treat chronic obstructive pulmonary disease (COPD), including chronic bronchitis, emphysema, or both, for better breathing and fewer flare-ups.
Umang Vohra (MD and Global CEO, Cipla Limited) said, "We are pleased to announce the ANDA submission for generic Advair Diskus to the US FDA. This marks a significant milestone and represents our commitment to increase patient access to complex treatment options in the respiratory space and will also play a major role in our strategy towards building a respiratory franchise in the US. Our unparalleled range of offerings in this space has established our position as lung leaders in India and emerging markets and we intend to extend this offering to our developed markets."
According to the IMS study (Dec 2019), Cipla ranked amongst the Top 2 companies globally for DPI and MDI devices. Cipla's borderless respiratory program, a slew of new devices launches and the ANDA filing of generic Advair Diskus are in line with its goal of becoming a global lung leader.
According to IQVIA (IMS Health), Advair Diskus and its generic equivalents had US sales of approximately US$ 2.9 billion for the 12-month period ending March 2020.
Last news about this category